A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer, showed results of a major trial that could change clinical practice.
Final results from the trial showed that olaparib — a pioneering type of drug called a PARP inhibitor, a cancer drug to target an inherited genetic fault — can be used successfully to treat prostate cancers with a weakness in their ability to repair damaged DNA.
The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients with advanced disease, the results showed.
The trial had already reported an improvement in disease development and outcome for this group of men with DNA repair faults in their tumors — but the final results published at this stage offer a longer follow-up and conclusively demonstrate an improvement in survival for men who were given olaparib.
The trial studied 387 men with advanced prostate cancer who had defects in one or more of 15 DNA repair genes.
Scientists at The Institute of Cancer Research (ICR), London, were the first to discover how olaparib could be targeted at tumors with faults in their ability to repair DNA.
They now expect the concluding results from the trial — presented at the European Society for Medical Oncology on Sunday and published in the journal The New England Journal of Medicine at the same time — to pave the way for regulatory approval of olaparib in prostate cancer in Europe and in the UK.
“I’m confident that our results will transform prostate cancer treatment – hopefully very soon,” said study co-leader Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London.
“We have shown that olaparib, a drug already approved for use in breast and ovarian cancer, can extend the lives of men with advanced prostate who have defects in the genes BRCA1, BRCA2 or ATM and who have been treated with enzalutamide or abiraterone,” said de Bono who is also Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.
“The FDA (Food and Drug Administration) has already approved olaparib for prostate cancer in the US and I hope that the final results of our trial will bring the authorization of this innovative drug to Europe and the UK as soon as possible,” he said.
Men whose tumors had genetic changes were assigned to two groups: one group for those with changes in BRCA1, BRCA2, or ATM, and another group for men with genetic changes in any other of the DNA repair genes studied.
Men were then randomly assigned to olaparib or standard hormone therapy.
DNA damage is the basic cause of cancer — but it is also a key weakness of cancer that can be exploited since cancer cells need to be able to repair their own DNA too.
In the final analysis of data from the “PROfound” trial, researchers found that olaparib blocked prostate cancer growth more effectively than the modern targeted hormone treatments abiraterone and enzalutamide in men with faulty DNA repair genes.
Patients with genetic alterations in the DNA repair genes BRCA1, BRCA2, or ATM who received olaparib had a median overall survival of 19.1 months, compared with 14.7 months for those on targeted hormone treatments, showed the results.
